Quidel Corporation (QDEL), a provider of rapid diagnostic testing solutions, saw its loss widen to $6.91 million or $0.20 a share for the quarter ended Jun. 30, 2014. Analysts on average had predicted net loss of $0.16 a share.

In the last year period, the company reported a loss of $1.76 million or $0.05 a share.

Revenue during the second-quarter climbed 6.00 percent to $31.49 million from $29.71 million in the last year period.

Gross margin contracted by 448 basis points over the last year period to 49.50 percent. Operating margin for the current period stood at negative 31.71 percent as compared to negative 23.41 percent for the previous year period.

The company reported operating loss of $9.98 million compared with $6.95 million in the previous year period.

''Despite the weak demand for flu products in the U.S. that persisted well into April, we did realize year-over-year growth across all major categories, thanks in large part to our new products, as well as our international business,'' said Douglas Bryant, president and CEO of Quidel Corporation.

''Our major product development programs are tracking to schedule, and in the quarter, we also received a couple regulatory clearances from the FDA that we believe can provide incremental near-term growth opportunities.''

Shares of Quidel Corporation gained $1 a share or 4.65 percent to close at $22.49 on Tuesday.